A Study of XW003 Injection in Chinese Adolescents With Obesity

NCT07143227 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of the experimental drug XW003, given as an injection, in Chinese adolescents who are obese.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 48 people

Who can join Ages 12–18 · all sexes Healthy volunteers accepted.

Timeline Started 2025-08 · est. completion 2026-04

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07143227 ↗

Description as written by the study sponsor.

The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XW003 injection in Chinese adolescents with obesity

Treatments tested

XW003 injection Drug

Subcutaneous injection
placebo with matching volume Drug

Subcutaneous injection

Main thing measured	Number and severity of adverse events
Sponsor	Hangzhou Sciwind Biosciences Co., Ltd.
Conditions studied	Obese Adolescents, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07143227 ↗